Psycheceutical

Psycheceutical Bioscience is a clinical-stage biotechnology company dedicated to developing innovative delivery technologies for psychedelic medicines. The company's flagship NeuroDirect platform is designed to deliver neuroactive compounds topically at the back of the neck, bypassing the blood-brain barrier to provide rapid therapeutic effects while minimizing systemic side effects and hallucinogenic experiences. Their lead program, a topical ketamine formulation, is currently being evaluated in clinical trials for the treatment of post-traumatic stress disorder (PTSD). By focusing on non-systemic delivery, Psycheceutical aims to make psychedelic-based therapies safer and more accessible for patients with various mental health and neurological disorders.